Most Read Articles
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.

Fendrix vs Engerix-B: Which vaccine is more effective against HBV in patients with IBD?

24 Nov 2020

Vaccination against hepatitis B virus (HBV) with single-dose Fendrix does not result in a higher response rate compared with double-dose Engerix-B in patients with inflammatory bowel disease (IBD), results of a study have shown, noting that a four-dose schedule is more effective than a three-dose regimen.

In addition, lower response rate is driven by older age and treatment with immunomodulators or antitumour necrosis factors (anti-TNF).

To compare the two vaccines against HBV in inflammatory bowel disease, the authors randomized 173 patients to receive either Engerix-B double dose (54 percent) or Fendrix single dose (46 percent) at months 0, 1, 2, and 6. They measured anti-HBs 2 months after the third and fourth doses and again at 6 and 12 months after the fourth dose. Response to vaccination was characterized by anti-HBs ≥100 IU/L.

Less than half of the patients (45 percent) responded after three doses and majority of them (71 percent) did after the fourth dose. The response rate after the fourth dose was 75 percent and 68 percent with Fendrix and Engerix-B, respectively (p=0.3).

Older age and treatment with steroids, immunomodulators, or anti-TNF correlated with impaired success or a lower probability of response, but the type of vaccine was not associated with the response.

Anti-HBs titre negativization occurred in 13 percent and 20 percent of patients after 6 and 12 months, respectively. Anti-HBs ≥100 IU/L after vaccination was the only factor associated with maintaining anti-HBs titres during follow-up.

“A high proportion of IBD patients with protective anti-HBs titres after vaccination loose them over time,” the authors said. “The risk of losing protective anti-HBs titres is increased in patients achieving anti-HBs <100 IU/L after the vaccination.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.